Literature DB >> 29417465

Reply to comments: duration of antimicrobial therapy for Gram-negative bacteremia secondary to urinary source of infection.

Majdi N Al-Hasan1,2, Avery N Nelson3, Julie Ann Justo4,5, Helmut Albrecht3,6, Joseph Kohn5, P Brandon Bookstaver4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29417465     DOI： 10.1007/s15010-018-1123-7

Source DB:  PubMed          Journal:  Infection        ISSN： 0300-8126            Impact factor:   3.553


× No keyword cloud information.
  5 in total

Review 1.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.

Authors:  Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper
Journal:  Clin Infect Dis       Date:  2011-03-01       Impact factor: 9.079

2.  Is bacteremia the decisive factor for the duration of antimicrobial therapy in bacteremic urinary tract infections?

Authors:  Stamatis Karakonstantis; Dafni Korela; Dimitra Kalemaki
Journal:  Infection       Date:  2018-01-16       Impact factor: 3.553

3.  Bacteremia complicating gram-negative urinary tract infections: a population-based study.

Authors:  Majdi N Al-Hasan; Jeanette E Eckel-Passow; Larry M Baddour
Journal:  J Infect       Date:  2010-01-28       Impact factor: 6.072

4.  Optimal duration of antimicrobial therapy for uncomplicated Gram-negative bloodstream infections.

Authors:  Avery N Nelson; Julie Ann Justo; P Brandon Bookstaver; Joseph Kohn; Helmut Albrecht; Majdi N Al-Hasan
Journal:  Infection       Date:  2017-05-06       Impact factor: 3.553

5.  Treatment duration of febrile urinary tract infection: a pragmatic randomized, double-blind, placebo-controlled non-inferiority trial in men and women.

Authors:  Cees van Nieuwkoop; Willize E van der Starre; Janneke E Stalenhoef; Anna M van Aartrijk; Tanny J K van der Reijden; Albert M Vollaard; Nathalie M Delfos; Jan W van 't Wout; Jeanet W Blom; Ida C Spelt; Eliane M S Leyten; Ted Koster; Hans C Ablij; Martha T van der Beek; Mirjam J Knol; Jaap T van Dissel
Journal:  BMC Med       Date:  2017-04-03       Impact factor: 8.775
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.